查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1499575

HIV 临床试验市场：按阶段、试验设计、介入类型、市场参与企业、赞助商 - 2024-2030 年全球预测

HIV Clinical Trials Market by Phase (Phase I, Phase II, Phase III), Study Design (Expanded Access Studies, Interventional Studies, Observational Studies), Type of Intervention, Participant, Sponsor - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年HIV临床试验市场规模为11.5亿美元，预计2024年将达12.3亿美元，2030年将达到18.8亿美元，复合年增长率为7.20%。

HIV 临床试验涉及严格的测试过程和预防或治癒人类免疫力缺乏病毒 (HIV) 感染的新治疗方法、药物和疗法的研究工作。鑑于爱滋病毒的多样性及其对不同人群的影响，临床试验对于提高医学知识和治疗能力至关重要。以爱滋病毒为重点的临床试验对于推进医学知识和製定更有效的策略来预防、检测和治疗爱滋病毒至关重要。全球爱滋病毒感染者人数不断增加，迫切需要有效的治疗方法，并扩大了爱滋病毒临床试验的数量。关于爱滋病毒预防和治疗的意识提升宣传活动正在促使研究人员扩大爱滋病毒临床试验。与爱滋病毒治疗相关的伦理问题阻碍了市场的成长。活性化的爱滋病毒研发活动和政府资助的增加为爱滋病毒临床试验市场创造了成长机会。

主要市场统计
基准年[2023] 11.5亿美元
预测年份 [2024] 12.3亿美元
预测年份 [2030] 18.8亿美元
复合年增长率（%） 7.20%

区域洞察

在雄厚的资金和先进的医疗保健系统的推动下，美洲的爱滋病毒临床试验数量持续增加。在大量政府和私人投资的支持下，美洲在爱滋病毒研究和发展方面处于世界领先地位。包括总统爱滋病紧急救援计画 (PEPFAR) 在内的倡议表明了对国内和世界各地消除爱滋病毒工作的坚定承诺。随着人们对爱滋病毒预防的认识不断提高，南美洲的爱滋病毒临床试验正迅速扩大。亚太地区高度发达，研究中心迅速增加，政府对新治疗方法和疫苗研究投入大量资金。儘管日本的爱滋病毒发病率较低，但它在涉及爱滋病毒的科学研究上投入了大量资金。印度人口众多，爱滋病毒感染率高，使其成为临床试验以及政府和国际共同投资的重要国家，特别是在学名药和负担得起的医疗保健解决方案的生产方面。欧盟（EU）国家在欧盟和国家资助机构的支持下积极参与爱滋病毒临床试验。在中东和非洲，由于爱滋病毒感染率高，特别是在撒哈拉以南非洲地区，针对爱滋病毒的临床试验数量逐渐增加。研究也着重于了解影响这些地区人口的独特遗传和环境因素，这对于根据当地需求制定干预措施至关重要。

FPNV定位矩阵

FPNV 定位矩阵对于评估供应商在 HIV 临床试验市场中的定位至关重要。此矩阵提供了对供应商的全面评估，并检验了与业务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估，供应商被分为代表其成功程度的四个像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可对 HIV 临床试验市场供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献，您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他关键指标。此外，该分析还提供了对该行业竞争性质的宝贵见解，包括在研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息，供应商可以做出更明智的决策并製定有效的策略，以在市场竞争中保持领先地位。

策略分析与建议

策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对目前在爱滋病毒临床试验市场中的地位进行全面评估，使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析，以确定核心优势和需要改进的领域。

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地感染爱滋病的人数不断增加
      • 製药公司和非营利组织增加了对爱滋病毒临床试验的投资活动
    • 抑制因素
      • 与爱滋病毒临床试验相关的高成本以及相关的研发成本
    • 机会
      • 政府增加爱滋病毒治疗和药物的核准
      • HIV临床试验技术和解决方案的进展
    • 任务
      • HIV 临床试验药物处方的复杂性
  • 市场区隔分析
    • 阶段：增加 III 期临床试验的数量，以提供新的治疗方法
    • 赞助：增加製药和生物製药公司的赞助，以提高药品的商业性可用性
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章 HIV 临床试验市场：依阶段、研究设计、介入类型、市场阶段

  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段

第七章 HIV 临床试验市场：阶段、试验设计、介入类型、市场研究设计

  • 扩大访问研究
  • 干预研究
  • 观察性研究

第八章 HIV 临床试验市场：依阶段、试验设计、介入类型、市场介入类型

  • 药物治疗
  • 疫苗

第九章 HIV 临床试验市场：依阶段、研究设计、介入类型和市场参与企业

  • 成人
  • 小儿科
  • 怀孕的女人

第 10 章 HIV 临床试验市场：阶段、试验设计、介入类型、市场赞助商

  • 非营利机构
  • 製药和生物製药公司

第十一章美洲爱滋病毒临床试验市场：阶段、试验设计、介入类型、市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区爱滋病毒临床试验市场：阶段、研究设计、介入类型、市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第 13 章：欧洲、中东和非洲 HIV 临床试验市场：阶段、研究设计、介入类型和市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 爱滋病临床试验小组的临床试验旨在提高爱滋病毒治疗的有效性和安全性
    • 研究表明，在不同人群中，注射剂卡博特韦在预防爱滋病毒方面优于口服 PrEP。
    • ReiThera、Ragon Institute 和 IAVI 开始创新 T 细胞 HIV 疫苗 HIVconsvX 的 I 期试验
  • 战略分析和建议

第15章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-7C50F273957B

[182 Pages Report] The HIV Clinical Trials Market size was estimated at USD 1.15 billion in 2023 and expected to reach USD 1.23 billion in 2024, at a CAGR 7.20% to reach USD 1.88 billion by 2030.

The HIV clinical trials involve rigorous testing processes and research activities where new treatments, drugs, and therapies are intended to prevent or cure human immunodeficiency virus (HIV) infection. Given the diversity of HIV and its impact on various demographic segments, the trials are vitally important in progressing medical knowledge and treatment capabilities. Clinical trials focused on HIV are crucial for advancing medical knowledge and developing more effective strategies for the prevention, detection, and treatment of HIV. The growing number of HIV cases globally fuels urgency and the need for effective treatments, subsequently expanding the number of HIV clinical trials. Enhanced awareness campaigns about HIV prevention and treatment encourage researchers to expand the clinical trials for HIV. Ethical concerns associated with the treatment of HIV hamper the market growth. Increasing research & development activities for HIV with rising government funding creates opportunities for the growth of the HIV clinical trials market.

KEY MARKET STATISTICS
Base Year [2023] USD 1.15 billion
Estimated Year [2024] USD 1.23 billion
Forecast Year [2030] USD 1.88 billion
CAGR (%) 7.20%

Regional Insights

In the Americas, the number of HIV clinical trials is continuously increasing due to robust funding and advanced healthcare systems. The Americas leads in global HIV research and development, supported by significant government and private investment. Initiatives, including, the President's Emergency Plan for AIDS Relief (PEPFAR), demonstrate a strong commitment to not only domestic but also global HIV control efforts. The HIV clinical trials in South America are rapidly expanding with rising awareness associated with the prevention of HIV. Asia-Pacific region is highly developing with rapidly increasing its research footprint and significant government investment in new therapies and vaccine research. Japan, while having a lower incidence of HIV, invests heavily in scientific research, including HIV. India's large population and high HIV prevalence make it a significant country for clinical trials, with both government and international collaborative investments, particularly in generic drug manufacturing and affordable healthcare solutions. European Union countries actively participate in HIV clinical trials, backed by EU and national funding bodies. In the Middle East and Africa, the number of clinical trials focusing on HIV is gradually increasing, driven by a high prevalence of the disease, particularly in sub-Saharan Africa. The research also emphasizes understanding the unique genetic and environmental factors affecting the population in these regions, which is critical for tailoring interventions to local needs.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the HIV Clinical Trials Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Increasing prevalence of AIDS disease worldwide
      • Growing investment activities by pharmaceutical and non-profit organizations for HIV clinical trials
    • Market Restraints
      • High costs associated with HIV clinical trials and associated research & development costs
    • Market Opportunities
      • Rising governmental approvals for HIV drugs and medications
      • Advancements in HIV clinical trial technologies and solutions
    • Market Challenges
      • Complexities in drug formulation of HIV clinical trials
  • Market Segmentation Analysis
    • Phase: Increasing the number of phase III clinical trials to make the new treatments available
    • Sponsor: Increasing sponsorship from pharmaceutical & biopharmaceutical companies to enhance commercial availability of medications
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the HIV Clinical Trials Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the HIV Clinical Trials Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Clinical Trial by AIDS Clinical Trials Group Seeks to Enhance HIV Treatment Efficacy and Safety

The AIDS Clinical Trials Group (ACTG), a renowned entity in HIV research, has recently launched a new clinical trial aimed at improving treatment strategies for HIV. This trial, referred to as the most significant of its kind in recent history, focuses on testing the effectiveness and safety of an innovative drug regimen. This regimen redefines standard care by enhancing its efficacy, reducing side effects, and simplifying treatment protocols. Through meticulous research and participant monitoring, the ACTG hopes to provide substantial evidence to influence future treatment guidelines and optimize outcomes for individuals living with HIV. [Published On: 2024-04-19]

Study Shows Injectable Cabotegravir Surpasses Oral PrEP in HIV Prevention Across Diverse Groups

ViiV Healthcare announced successful results from clinical trials of cabotegravir, a long-acting injectable formulation. This innovative treatment, administered bi-monthly, has shown high efficacy in reducing the risk of HIV infection across diverse population groups. In these trials, cabotegravir outperformed daily oral pre-exposure prophylaxis (PrEP), demonstrating fewer HIV infections among participants who received the injection compared to those who took oral PrEP. These findings mark a promising advancement in HIV prevention strategies, offering an effective and more convenient alternative for individuals at risk of HIV, potentially improving adherence and overall public health outcomes. [Published On: 2024-03-04]

ReiThera, Ragon Institute, and IAVI Launch Phase I Trials for Innovative T-Cell HIV Vaccine, HIVconsvX

ReiThera Srl, the Ragon Institute, and IAVI have embarked on a collaborative initiative to progress a promising T-cell HIV vaccine candidate, HIVconsvX, into Phase I clinical evaluation. This collaborative effort marks a significant step in HIV vaccine research, focusing on a vaccine designed to trigger a broad and potent immune response. By targeting highly conserved regions across various HIV strains, HIVconsvX aims to provide robust protection against this globally prevalent virus. The advancement to Phase I trials showcases the potential of this innovative approach and underscores the collaborative model among leading research institutions and biotech firms in pioneering solutions for some of the most challenging health issues. [Published On: 2024-01-22]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the HIV Clinical Trials Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the HIV Clinical Trials Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., American Gene Technologies Inc, AstraZeneca PLC, Bayer AG, BioNTech SE, Boehringer Ingelheim International GmbH, Cipla Ltd., CSL Limited, Daiichi Sankyo Company, Limited, Eli Lilly and Company, Emcure Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Moderna, Inc., Mylan N.V., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Sun Pharmaceutical Industries Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the HIV Clinical Trials Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Phase
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
  • Study Design
    • Expanded Access Studies
    • Interventional Studies
    • Observational Studies
  • Type of Intervention
    • Drug Therapy
    • Vaccines
  • Participant
    • Adults
    • Pediatric
    • Pregnant Women
  • Sponsor
    • Non Profit Organizations
    • Pharmaceutical & Biopharmaceutical Companies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of AIDS disease worldwide
      • 5.1.1.2. Growing investment activities by pharmaceutical and non-profit organizations for HIV clinical trials
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with HIV clinical trials and associated research & development costs
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising governmental approvals for HIV drugs and medications
      • 5.1.3.2. Advancements in HIV clinical trial technologies and solutions
    • 5.1.4. Challenges
      • 5.1.4.1. Complexities in drug formulation of HIV clinical trials
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Phase: Increasing the number of phase III clinical trials to make the new treatments available
    • 5.2.2. Sponsor: Increasing sponsorship from pharmaceutical & biopharmaceutical companies to enhance commercial availability of medications
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. HIV Clinical Trials Market, by Phase

  • 6.1. Introduction
  • 6.2. Phase I
  • 6.3. Phase II
  • 6.4. Phase III
  • 6.5. Phase IV

7. HIV Clinical Trials Market, by Study Design

  • 7.1. Introduction
  • 7.2. Expanded Access Studies
  • 7.3. Interventional Studies
  • 7.4. Observational Studies

8. HIV Clinical Trials Market, by Type of Intervention

  • 8.1. Introduction
  • 8.2. Drug Therapy
  • 8.3. Vaccines

9. HIV Clinical Trials Market, by Participant

  • 9.1. Introduction
  • 9.2. Adults
  • 9.3. Pediatric
  • 9.4. Pregnant Women

10. HIV Clinical Trials Market, by Sponsor

  • 10.1. Introduction
  • 10.2. Non Profit Organizations
  • 10.3. Pharmaceutical & Biopharmaceutical Companies

11. Americas HIV Clinical Trials Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific HIV Clinical Trials Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa HIV Clinical Trials Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Clinical Trial by AIDS Clinical Trials Group Seeks to Enhance HIV Treatment Efficacy and Safety
    • 14.3.2. Study Shows Injectable Cabotegravir Surpasses Oral PrEP in HIV Prevention Across Diverse Groups
    • 14.3.3. ReiThera, Ragon Institute, and IAVI Launch Phase I Trials for Innovative T-Cell HIV Vaccine, HIVconsvX
  • 14.4. Strategy Analysis & Recommendation

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. HIV CLINICAL TRIALS MARKET RESEARCH PROCESS
  • FIGURE 2. HIV CLINICAL TRIALS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. HIV CLINICAL TRIALS MARKET DYNAMICS
  • FIGURE 7. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. HIV CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. HIV CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HIV CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EXPANDED ACCESS STUDIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EXPANDED ACCESS STUDIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DRUG THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DRUG THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY VACCINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY VACCINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ADULTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ADULTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PEDIATRIC, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PREGNANT WOMEN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PREGNANT WOMEN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON PROFIT ORGANIZATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON PROFIT ORGANIZATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 57. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 58. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 59. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 60. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 61. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 62. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 63. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 64. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 65. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 66. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 67. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 68. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 69. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 70. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 71. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 72. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 73. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 74. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 75. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 76. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 77. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 78. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 79. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 80. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 81. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 82. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 83. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 84. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 85. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 86. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 87. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 88. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 89. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 90. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 91. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 92. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 93. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 94. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 95. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 96. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 97. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 98. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 99. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 100. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 101. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 102. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 103. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 104. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 105. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 106. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 107. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 108. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 122. AUSTRALIA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 124. AUSTRALIA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 126. AUSTRALIA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 128. AUSTRALIA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 130. AUSTRALIA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 131. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 132. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 133. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 134. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 135. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 136. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 137. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 138. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 139. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 140. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 141. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 142. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 143. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 144. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 145. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 146. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 147. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 148. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 149. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 150. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 151. INDONESIA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 152. INDONESIA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 153. INDONESIA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 154. INDONESIA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 155. INDONESIA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 156. INDONESIA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 157. INDONESIA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 158. INDONESIA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 159. INDONESIA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 160. INDONESIA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 161. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 162. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 163. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 164. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 165. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 166. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 167. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 168. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 169. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 170. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 171. MALAYSIA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 172. MALAYSIA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 173. MALAYSIA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 174. MALAYSIA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 175. MALAYSIA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 176. MALAYSIA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 177. MALAYSIA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 178. MALAYSIA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 179. MALAYSIA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 180. MALAYSIA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 181. PHILIPPINES HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 182. PHILIPPINES HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 184. PHILIPPINES HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 186. PHILIPPINES HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 188. PHILIPPINES HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 190. PHILIPPINES HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 191. SINGAPORE HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 192. SINGAPORE HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 193. SINGAPORE HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 194. SINGAPORE HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 195. SINGAPORE HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 196. SINGAPORE HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 197. SINGAPORE HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 198. SINGAPORE HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 199. SINGAPORE HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 200. SINGAPORE HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 201. SOUTH KOREA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 202. SOUTH KOREA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 203. SOUTH KOREA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 204. SOUTH KOREA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 206. SOUTH KOREA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 208. SOUTH KOREA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 210. SOUTH KOREA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 211. TAIWAN HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 212. TAIWAN HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 213. TAIWAN HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 214. TAIWAN HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 215. TAIWAN HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 216. TAIWAN HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 217. TAIWAN HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 218. TAIWAN HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 219. TAIWAN HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 220. TAIWAN HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 221. THAILAND HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 222. THAILAND HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 223. THAILAND HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 224. THAILAND HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 225. THAILAND HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 226. THAILAND HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 227. THAILAND HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 228. THAILAND HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 229. THAILAND HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 230. THAILAND HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 231. VIETNAM HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 232. VIETNAM HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 233. VIETNAM HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 234. VIETNAM HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 235. VIETNAM HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 236. VIETNAM HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 237. VIETNAM HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 238. VIETNAM HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 239. VIETNAM HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 240. VIETNAM HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 253. DENMARK HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 254. DENMARK HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 255. DENMARK HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 256. DENMARK HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 257. DENMARK HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 258. DENMARK HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 259. DENMARK HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 260. DENMARK HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 261. DENMARK HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 262. DENMARK HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 263. EGYPT HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 264. EGYPT HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 265. EGYPT HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 266. EGYPT HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 267. EGYPT HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 268. EGYPT HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 269. EGYPT HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 270. EGYPT HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 271. EGYPT HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 272. EGYPT HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 273. FINLAND HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 274. FINLAND HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 275. FINLAND HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 276. FINLAND HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 277. FINLAND HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 278. FINLAND HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 279. FINLAND HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 280. FINLAND HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 281. FINLAND HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 282. FINLAND HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 283. FRANCE HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 284. FRANCE HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 285. FRANCE HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 286. FRANCE HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 287. FRANCE HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 288. FRANCE HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 289. FRANCE HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 290. FRANCE HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 291. FRANCE HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 292. FRANCE HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 293. GERMANY HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 294. GERMANY HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 295. GERMANY HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 296. GERMANY HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 297. GERMANY HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 298. GERMANY HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 299. GERMANY HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 300. GERMANY HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 301. GERMANY HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 302. GERMANY HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 303. ISRAEL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 304. ISRAEL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 305. ISRAEL HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 306. ISRAEL HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 307. ISRAEL HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 308. ISRAEL HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 309. ISRAEL HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 310. ISRAEL HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 311. ISRAEL HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 312. ISRAEL HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 313. ITALY HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 314. ITALY HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 315. ITALY HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 316. ITALY HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 317. ITALY HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 318. ITALY HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 319. ITALY HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 320. ITALY HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 321. ITALY HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 322. ITALY HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 323. NETHERLANDS HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 324. NETHERLANDS HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 325. NETHERLANDS HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 326. NETHERLANDS HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 327. NETHERLANDS HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 328. NETHERLANDS HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 329. NETHERLANDS HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 330. NETHERLANDS HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 331. NETHERLANDS HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 332. NETHERLANDS HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 333. NIGERIA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 334. NIGERIA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 335. NIGERIA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 336. NIGERIA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 337. NIGERIA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 338. NIGERIA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 339. NIGERIA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 340. NIGERIA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2024-2030 (USD MILLION)
  • TABLE 341. NIGERIA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2023 (USD MILLION)
  • TABLE 342. NIGERIA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2024-2030 (USD MILLION)
  • TABLE 343. NORWAY HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2023 (USD MILLION)
  • TABLE 344. NORWAY HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2024-2030 (USD MILLION)
  • TABLE 345. NORWAY HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2023 (USD MILLION)
  • TABLE 346. NORWAY HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2024-2030 (USD MILLION)
  • TABLE 347. NORWAY HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2023 (USD MILLION)
  • TABLE 348. NORWAY HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2024-2030 (USD MILLION)
  • TABLE 349. NORWAY HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2023 (USD MILLION)
  • TABLE 350. NORWAY HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPA